Cydney Fenton
Pediatric Endocrinology · Boise, IDNPI 1497788921
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,240 of the $23,840 with a category attached, or 76.5%. 33 manufacturers reported payments, led by AstraZeneca at 51.4% of the total.
Across 111 payments — averaging $214.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$12K
- Dexcom, Inc.$8K
- Eton Pharmaceuticals, Inc.$2K
- Novo Nordisk$437
- Rhythm Pharmaceuticals, Inc.$282
- Abbott$105
- plus $975 from 27 others
Across 2 payments — averaging $1327.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$3K
What the payments were for
- Consulting fees$1,5006%
- Speaking & faculty fees$18,24077%
- Travel & lodging$1,7787%
- Food & beverage$2,28810%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 24 | $12,253 |
| Dexcom, Inc. | 7 | $8,288 |
| Eton Pharmaceuticals, Inc. | 2 | $1,500 |
| Novo Nordisk | 21 | $437 |
| Rhythm Pharmaceuticals, Inc. | 1 | $282 |
| Abbott | 6 | $105 |
| Ascendis Pharma Endocrinology Inc | 4 | $100 |
| Myovant Sciences Inc. | 4 | $92 |
| Tandem Diabetes Care, Inc. | 2 | $68 |
| Kyowa Kirin, Inc. | 3 | $65 |
| Lilly USA, LLC | 4 | $61 |
| AbbVie | 4 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| GSK | 3 | $42 |
| Companion Medical, Inc. | 1 | $36 |
| Ascensia Diabetes Care US Inc. | 2 | $34 |
| Sanofi Pasteur Inc. | 2 | $28 |
| Johnson & Johnson | 2 | $27 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Neuronetics, Inc. | 1 | $25 |
| Insulet Corporation | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| IBSA Pharma Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Merck | 1 | $19 |
| Antares Pharma, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Biomarin Pharmaceutical Inc. | 1 | $15 |
| Medtronic | 1 | $14 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM CGM$4,787
- DEXCOM G6 CGM SYSTEM$3,400
- Strensiq$2,430
- Alkindi$1,500
- Saxenda$121
How this compares
Too few pediatric endocrinology providers in Idahoto place this figure against a meaningful peer group, so we don't.
Other pediatric endocrinology in Boise
- Daniel FlynnBoise$107K
- Joshua SmithIdaho Falls$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.